BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Elixiron Advances Precision Immunotherapy Strategy with Encouraging Alzheimer's Data

Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmun...

June 15, 2026 | News

Rejuvenate Bio and Merck Animal Health Join Forces on Novel Animal Health Gene Therapy Programme

-- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, congratulates its portfolio company Rejuvenate...

June 15, 2026 | News

Akeso Expands Immunology Franchise with Approval of Gumokimab for Psoriasis

Akeso, Inc. announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-devel...

June 15, 2026 | News

Simcere and Stanford Medicine Partner to Advance First-in-Class Therapy for Idiopathic Pulmonary Fibrosis

Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory stu...

June 15, 2026 | News

PromptBio Launches Agentic AI Platform to Accelerate Scientific Discovery

The PromptBio Platform combines conversational AI with multi-agent orchestration to accelerate discovery from hypotheses to insights PromptBio, a Californ...

June 11, 2026 | News

China Approves First-in-Human Trial of Antengene’s ATG-201 for Autoimmune Diseases

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, d...

June 12, 2026 | News

China Clears Adcentrx’s ADRX 0405 For Clinical Development In Advanced Solid Tumours

Follows initiation of Phase 1a/1b study in the U.S. Adcentrx intends to include clinical centers in China to broaden geographic repr...

June 10, 2026 | News

Waters Launches Industry First RP Column Platform To Accelerate GLP 1 And LNP Drug Development

Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottleneck...

June 10, 2026 | News

Chime Biologics Expands Manufacturing Capacity With New GMP-2 Facility And AI Powered Megafactory Vision

Chime Biologics’ manufacturing expansion builds on a decade of collaboration enabled by Cytiva’s modular manufacturing platform ...

June 10, 2026 | News

OriCell Advances First GPC3 CAR T Therapy Into Confirmatory Phase II Trial for Advanced Liver Cancer

OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") , announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101,...

June 08, 2026 | News

Chime Biologics And Daewoong Pharmaceutical Partner To Advance Global Dupilumab Biosimilar Development

VMS Group is pleased to share that our portfolio company, Chime Biologics, in which we are also the controlling shareholder, has announced a strategic...

June 09, 2026 | News

Mabwell's First In Class Autoimmune Antibody 9MW5211 Wins China Clinical Trial Approval for IBD

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently...

June 08, 2026 | News

LongBio Pharma Debuts on Hong Kong Exchange With HK$10.7 Billion Valuation

LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and autoimmune diseases in China, liste...

June 08, 2026 | News

Vcare PharmaTech Secures China Approval for Next Generation TRK Inhibitor Eratrectinib in NTRK Fusion Positive Solid Tumours

NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the...

June 08, 2026 | News

Stay Connected